AxioMx Launches AxioMx MembraneProSelect™ Service
Posted on Sep 22, 2015
September 22, 2015. AxioMx announced the launch of AxioMx MembraneProSelect™, a new service that enables the development of recombinant antibodies that recognize the native conformation of cell membrane protein extracellular domains (ECDs).
The conformation of a cell membrane protein is heavily influenced by integration within membrane lipid bilayers. This presents a challenge during antibody development as peptides or purified membrane proteins outside of their native context are often used as the antigen source. Antibodies generated against these types of isolated membrane proteins and peptides often do not recognize the target when displayed on the surface of a cell. This limits their use in research, diagnostics, and therapeutics for targeting important classes of molecules, including ion channels, G-protein coupled receptors, receptor tyrosine kinases, integrins, and toll-like receptor proteins.
AxioMx has overcome this challenge by applying its unique phage display-based antibody development platform to whole cell screening to isolate membrane protein-specific antibodies that recognize the target in its native conformation. AxioMx MembraneProSelect enables the rapid development of monoclonal antibodies to the ECDs of cell membrane proteins in as little as six or seven weeks.
“Researchers now have a resource for the development of research-purposed or therapeutic-candidate antibodies that specifically and effectively bind the ECDs of their cell membrane proteins of interest,” said Tom Thompson, vice president of sales and marketing, at AxioMx. “We believe this fills a large, unmet life science marketplace need and it will help scientists to develop better antibodies to an important class of targets that have been difficult to address with traditional animal-based methods.”
The final AxioMx MembraneProSelect deliverable is a recombinant antibody. Customers may choose their final recombinant antibody format, typically a scFv (single-chain variable fragment) or an IgG. Unlike conventional antibody generation processes, AxioMx’s methods are completely in vitro and animal-free.
About AxioMx Inc.
AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics, and proteomics organizations. AxioMx’s unique platform of proprietary phage display libraries, Rapid Liquid Screening, and affinity maturation methods enables the fast delivery of recombinant antibodies with high specificity, affinity, and reproducibility that are optimized to perform a desired application. The company offers a full range of custom antibody discovery and development services for the research, diagnostic, and therapeutic marketplaces, including the new AxioMx Express custom antibody service which provides 5 week development of research use recombinant antibodies. For more information about AxioMx, please visit www.axiomxinc.com.